Endocrine Abstracts

Bisphosphonates (BPs) are synthetic analogues of pyrophosphate that inhibit osteoclast-mediated bone resorption and reduce bone turnover. Of proven therapeutic benefit, licensed indications for clinical use of BPs include, 1) prevention of osteoporotc fractures, 2) management of bone pain (Paget’s disease, metastatic breast cancer & myeloma) and 3) treatment of hypercalcaemia of malignancy. The perceived safety of BPs has, however, resulted in growth of ‘off-labe...

History: A 50-year-old lady presented in March-08 with clinical features consistent with Cushings syndrome and was diagnosed with pituitary driven ACTH-dependent Cushings disease on the basis of the following investigations; elevated 24 hours urinary free cortisol 1660 nmol/l; baseline cortisol 1230 nmol/l; serum cortisol levels post low dose and subsequent high dose dexamethasone suppression tests 722 nmol/l and 1032 nmol/l respectively; serum cortisol post 100 mcg CRH 979 nm...

Introduction: As there are scarce data on the clinical case load and multidisciplinary input provided for patients with osteogenesis imperfecta (OI), we performed a survey of patients with OI attending bone and genetic clinics in Glasgow.Methods: Clinical details of 53 children(M:28) and 23 adults(M:9) were obtained by a review of case records.Results: The median age at presentation in children was 4.5 yrs (range 0.2–13.5), wi...

Objectives and methods: The HORIZON-PFT is a multinational, 3-year, randomized, double-blind, placebo-controlled trial evaluating the potential of once-yearly zoledronic acid (ZOL) 5 mg, infused over 15 minutes, to decrease risk of fracture in 7736 postmenopausal osteoporotic women 65–89 years of age.Results: Treatment with ZOL 5 mg resulted in significant relative risk reductions in morphometric vertebral fracture of 70% vs PBO (3.8% vs 12.8%; 95% ...